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a b s t r a c t
Aim: To systematically review the literature to compare the use of DPP4 inhibitors vs sulpho-
nylurea in type 2 diabetic Muslim patients who fast in Ramadan, with regards to its safety,
tolerability, glycemic control, and body weight changes.
Methods: All English-language medical literature published from inception till October 2014
which met the inclusion criteria were reviewed and analyzed.
Results: A total of nine papers were included, reviewed and analyzed. The total sample
size was 4276 patients. All studies used either of the two DPP4 inhibitors – Vildagliptin
or Sitagliptin, vs sulphonylurea or meglitinides. Patients receiving DPP4 inhibitors were less
likely to develop symptomatic hypoglycemia (risk ratio 0.46; 95% CI, 0.30–0.70), confirmed
hypoglycemia (risk ratio 0.36; 95% CI, 0.21–0.64) and severe hypoglycemia (risk ratio 0.22;
95% CI, 0.10–0.53) compared with patients on sulphonylureas. There was no statistically
significant difference in HbA1C changes comparing Vildagliptin and sulphonylurea.
Conclusion: DPP4 inhibitor is a safer alternative to sulphonylurea in Muslim patients withtype 2 diabetes mellitus who fast during the month of Ramadan as it is associated with
lower risk of symptomatic, confirmed and severe hypoglycemia, with efficacy comparable
to sulphonylurea.
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